parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (152 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.50
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 38	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 12353

APBB1 in dopamine neurons, braak-0.27 (p 0.487) → +0.04 (p 0.928)receipt 12360
APBB1 in oligodendrocytes, braak-0.23 (p 0.555) → -0.59 (p 0.092)receipt 12359

receipt 12360: APBB1 in dopamine neurons, braak

power: full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.444, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.471, n 18). could be the mix.
skeptic: leave-one-out range -0.19 to +0.02, sign flips 2; without severely affected donors -0.12 (p 0.640, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APBB1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12359: APBB1 in oligodendrocytes, braak

power: full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.38 (p 0.118, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.36 (p 0.142, n 18). could be the mix.
skeptic: leave-one-out range -0.45 to -0.22, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for APBB1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts